Cofactor Genomics
Cofactor Genomics, based in St. Louis, MO, specializes in RNA-based diagnostics and predictive immune modeling to enhance patient outcomes in immunotherapy, particularly in cancer treatment.
Company Overview
Cofactor Genomics is a healthcare diagnostics company based in St. Louis, MO, USA. With a small team of 13 employees, the company is known for using RNA and Predictive Immune Modeling to develop better biomarkers and improve patient outcomes. Participating in the Y Combinator batch S15, Cofactor Genomics targets its services across the United States and has a partly remote workforce.
Innovative Technology
Cofactor Genomics leverages RNA and Predictive Immune Modeling to enhance diagnostic precision. Their technology has been rigorously validated by esteemed organizations like CAP and AMP. It has also been published in the Journal of Molecular Diagnostics. A pivotal clinical study demonstrated their technology's superiority in predicting patient responses to immunotherapy, a finding presented by Cancer Physicians at the NCCN. This technology's application is expanding to cover up to 50% of cancers diagnosed in the U.S.
PREDAPT Trial
Cofactor Genomics is a key participant in the national PREDAPT Trial, which evaluates the OncoPrism assay for predicting patient responses to immunotherapy across 11 solid tumor cancers. The trial has garnered partnerships with more than 24 healthcare systems, including notable institutions like Intermountain Healthcare, Cleveland Clinic, Stanford University, and Mayo Clinic.
Investors and Partnerships
The ongoing research and development at Cofactor Genomics is backed by prominent investors such as Menlo Ventures, DCVC, and Ascension Ventures. Their client and partner portfolio includes esteemed healthcare systems like Intermountain Healthcare, Cleveland Clinic, Stanford University, UC San Diego, Mayo Clinic, and CoxHealth.
Focus on Immune-Oncology
Cofactor Genomics is actively pursuing indications in various immune-oncology fields including HNSCC, NSCLC, CRC, Urothelial, and Melanoma. Their diagnostic pipeline is robust, advancing from stages of feasibility and immune signal detection to clinical study validation.
